| Arm A (n = 32) | Arm B (n = 31) | Total (n = 63) | |||
---|---|---|---|---|---|---|
 | n | Percent | n | Percent | n | Percent |
Age | Â | Â | Â | Â | Â | Â |
   Median |  | 70 |  | 65 |  | 68 |
   Range |  | 50-89 |  | 45-80 |  | 45-89 |
Race | Â | Â | Â | Â | Â | Â |
   White | 30 | 94% | 28 | 90% | 58 | 92% |
   Black | 1 | 3% | 3 | 10% | 4 | 6% |
   Hispanic | 1 | 3% | 0 | 0% | 1 | 2% |
ECOG PS | Â | Â | Â | Â | Â | Â |
   0 | 15 | 47% | 17 | 55% | 32 | 51% |
   1 | 16 | 50% | 12 | 39% | 28 | 44% |
   2 | 1 | 3% | 2 | 6% | 3 | 5% |
Extent of Disease | Â | Â | Â | Â | Â | Â |
   Measurable, Non-Osseous Disease Present | 14 | 44% | 13 | 42% | 27 | 43% |
   Evaluable, Osseous Disease Present | 28 | 88% | 30 | 97% | 58 | 92% |
   Evaluable, Non-Osseous Disease Present | 13 | 41% | 12 | 39% | 25 | 40% |
   Elevated PSA | 32 | 100% | 30 | 97% | 62 | 98% |
Metastatic Disease | Â | Â | Â | Â | Â | Â |
   Lung | 4 | 13% | 4 | 13% | 8 | 13% |
   Liver | 3 | 9% | 3 | 10% | 6 | 10% |
   Bone | 28 | 88% | 29 | 94% | 57 | 90% |
   Bone Marrow | 0 | 0% | 1 | 3% | 1 | 2% |
   Pleura | 1 | 3% | 0 | 0% | 1 | 2% |
   Other | 11 | 34% | 9 | 29% | 20 | 32% |
Prior Treatment | Â | Â | Â | Â | Â | Â |
   Orchiectomy | 10 | 31% | 7 | 23% | 17 | 27% |
   Prostatectomy | 17 | 53% | 15 | 48% | 32 | 51% |
   Other Surgery | 19 | 59% | 20 | 65% | 39 | 62% |
   Radiation Therapy | 18 | 56% | 20 | 65% | 38 | 60% |
   Hormonal Therapy | 31 | 97% | 29 | 94% | 60 | 95% |
   Biologic Response Modifier | 4 | 13% | 2 | 6% | 6 | 10% |